clinical trial · NCT04202965
PTG-300 in Subjects With Hereditary Hemochromatosis
Hereditary HemochromatosisPTG-300
brief summary
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
started
Mar 19, 2020
primary completion
Oct 6, 2021
completion
Feb 15, 2022
last updated
Aug 20, 2025
detailed description
This study is a multicenter, open-label study. The objective of the study is to assess the effect of PTG-300 on transferrin saturation (TSAT) and serum iron in adult hereditary hemochromatosis patients.
official title
Open-label Study of PTG-300 in Subjects With Hereditary Hemochromatosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol